Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

Theodore S. Hong; Clemens Grassberger; Beow Y. Yeap; Wenqing Jiang; Jennifer Y. Wo; Lipika Goyal; Jeffrey W. Clark; Christopher H. Crane; Eugene J. Koay; Simona Dima; Christine E. Eyler; Irinel Popescu; Thomas F. DeLaney; Andrew X. Zhu; Dan G. Duda

doi:10.1038/s41698-018-0065-y

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

Theodore S. Hong, Clemens Grassberger, Beow Y. Yeap, Wenqing Jiang, Jennifer Y. Wo, Lipika Goyal, Jeffrey W. Clark, Christopher H. Crane, Eugene J. Koay, Simona Dima, Christine E. Eyler, Irinel Popescu, Thomas F. DeLaney, Andrew X. Zhu, Dan G. Duda

Houston Methodist

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy—a Childs−Turcotte−Pugh (CTP) score increase of 1 point or more—occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p = 0.015). Both the increase in CTP score (p = 0.034) and the pretreatment plasma HGF (p = 0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p = 0.0027) and with Model for End-stage Liver Disease (MELD) score (p < 0.0001), but not with OS in surgical liver cancer patients. Pretreatment plasma HGF is a candidate biomarker for patient selection for radiotherapy.

Original language	English (US)
Article number	22
Journal	npj Precision Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1038/s41698-018-0065-y
State	Published - Dec 1 2018

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1038/s41698-018-0065-y

Cite this

Hong, T. S., Grassberger, C., Yeap, B. Y., Jiang, W., Wo, J. Y., Goyal, L., Clark, J. W., Crane, C. H., Koay, E. J., Dima, S., Eyler, C. E., Popescu, I., DeLaney, T. F., Zhu, A. X., & Duda, D. G. (2018). Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. npj Precision Oncology, 2(1), Article 22. https://doi.org/10.1038/s41698-018-0065-y

Hong, TS, Grassberger, C, Yeap, BY, Jiang, W, Wo, JY, Goyal, L, Clark, JW, Crane, CH, Koay, EJ, Dima, S, Eyler, CE, Popescu, I, DeLaney, TF, Zhu, AX & Duda, DG 2018, 'Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy', npj Precision Oncology, vol. 2, no. 1, 22. https://doi.org/10.1038/s41698-018-0065-y

@article{42ecce06978d443797a6ae6160765abd,

title = "Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy",

abstract = "Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy—a Childs−Turcotte−Pugh (CTP) score increase of 1 point or more—occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p = 0.015). Both the increase in CTP score (p = 0.034) and the pretreatment plasma HGF (p = 0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p = 0.0027) and with Model for End-stage Liver Disease (MELD) score (p < 0.0001), but not with OS in surgical liver cancer patients. Pretreatment plasma HGF is a candidate biomarker for patient selection for radiotherapy.",

author = "Hong, {Theodore S.} and Clemens Grassberger and Yeap, {Beow Y.} and Wenqing Jiang and Wo, {Jennifer Y.} and Lipika Goyal and Clark, {Jeffrey W.} and Crane, {Christopher H.} and Koay, {Eugene J.} and Simona Dima and Eyler, {Christine E.} and Irinel Popescu and DeLaney, {Thomas F.} and Zhu, {Andrew X.} and Duda, {Dan G.}",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41698-018-0065-y",

language = "English (US)",

volume = "2",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

AU - Hong, Theodore S.

AU - Grassberger, Clemens

AU - Yeap, Beow Y.

AU - Jiang, Wenqing

AU - Wo, Jennifer Y.

AU - Goyal, Lipika

AU - Clark, Jeffrey W.

AU - Crane, Christopher H.

AU - Koay, Eugene J.

AU - Dima, Simona

AU - Eyler, Christine E.

AU - Popescu, Irinel

AU - DeLaney, Thomas F.

AU - Zhu, Andrew X.

AU - Duda, Dan G.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy—a Childs−Turcotte−Pugh (CTP) score increase of 1 point or more—occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p = 0.015). Both the increase in CTP score (p = 0.034) and the pretreatment plasma HGF (p = 0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p = 0.0027) and with Model for End-stage Liver Disease (MELD) score (p < 0.0001), but not with OS in surgical liver cancer patients. Pretreatment plasma HGF is a candidate biomarker for patient selection for radiotherapy.

AB - Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy—a Childs−Turcotte−Pugh (CTP) score increase of 1 point or more—occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p = 0.015). Both the increase in CTP score (p = 0.034) and the pretreatment plasma HGF (p = 0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p = 0.0027) and with Model for End-stage Liver Disease (MELD) score (p < 0.0001), but not with OS in surgical liver cancer patients. Pretreatment plasma HGF is a candidate biomarker for patient selection for radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85065210553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065210553&partnerID=8YFLogxK

U2 - 10.1038/s41698-018-0065-y

DO - 10.1038/s41698-018-0065-y

M3 - Article

AN - SCOPUS:85065210553

SN - 2397-768X

VL - 2

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 22

ER -

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this